After the floods from Hurricane Harvey totaled her car, Rahel Abraham wanted to find a solution. ClimaGuard/Facebook

Floodwaters from Hurricane Harvey seriously damaged about 600,000 vehicles in the Houston area, driving millions upon millions of dollars in auto insurance claims. Rahel Abraham's 2008 Infiniti G35 was among them.

Rather than merely moving on from the hurricane, though, Abraham — drawing upon her experience as an engineer in Houston's petrochemical industry — invented something that she foresaw shielding cars from the economic wrath of flooding.

Now, Abraham's brainchild forms the backbone of her Houston-based startup, ClimaGuard LLC. The next several weeks promise to be momentous for the business — Abraham will enter the 12-week DivInc business accelerator program in Austin in late August, and the company's first product is set to hit the market in early September.

ClimaGuard's waterproof, temperature-resistant, portable Temporary Protective Enclosure (TPE) can entirely cover a compact car, sedan, or midsize SUV. It comes in three sizes; the cost ranges from $349 to $499.

To protect a vehicle, someone sets a TPE on the ground, a driveway, or another flat surface, then drives the vehicle onto the bottom part of the product, and connects the bottom and top parts with the zipper. Abraham likens it to a clamshell preserving a pearl.

Once the vehicle is inside the TPE, it can be anchored with straps to a sturdy fixture. It's designed to withstand up to three feet of water and keep the vehicle from floating away.

One person can set up a TPE in less than five minutes, Abraham says.

She hopes to team up with auto insurers to offer discounts for policyholders that have a TPE. This, Abraham says, would spur more people to buy the product.

"My goal is not to make it to where it's an exclusive product — available only to those who can afford it — but I want to be able to help those who it would make even more of an economic impact for," Abraham says.

Among potential customers for the TPE are car owners, homeowners, small businesses, first-responder organizations, and nonprofit agencies, Abraham says. Other than vehicles, the product could protect valuables like antique pianos and restaurant gear, according to Abraham.

The sense of "helplessness and vulnerability" Abraham felt after her car was lost in Hurricane Harvey propelled her to devise ClimaGuard's TPE, she says, so that others might avoid enduring the sort of "stressful and traumatic" ordeal that she did.

Another catalyst: After hatching the idea for the TPE, Abraham learned that more than 41 million Americans live in federally designated flood zones, and that flooding is the costliest type of natural disaster in the U.S. and is forecast to occur more frequently. That research "validated my gut feeling," she says.

Abraham, a first-time entrepreneur, founded the bootstrapped startup in 2018, just a year after Harvey. Today, she's the only full-time employee of ClimaGuard. She holds a bachelor's in chemical engineering from the University of Texas at Austin and a master's degree in environmental engineering from the University of Houston.

Abraham says she hopes participating in the 12-week DivInc accelerator program in Austin will broaden her business network and hone her marketing skills. ClimaGuard was among 13 companies selected for this fall's DivInc group, which is sponsored by JPMorgan Chase.

DivInc aims to diversify the startup environment by offering workshops, mentoring, and business-strategy assistance to underrepresented entrepreneurs — people of color and women. The Austin-based nonprofit organization chooses participants through an application process that its program director, Brooke Turner, describes as being "extremely competitive" this year.

"It's tough being a developer or entrepreneur when no one looks like you when you walk into a room of other developers or entrepreneurs," DivInc co-founder Ashley Jennings told Crunchbase in 2017. "How can they feel that they fit in? So what we have now is an opportunity to create role models with this generation."
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totalling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.